{"ticker": {"uuid": "64205c28-f557-4f7d-bb17-7c47bcc87841", "symbol": "TLX", "name": "Telix Pharmaceuticals Limited", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Telix opens radiopharmaceutical facility in Australia for cancer treatment", "summary": "", "url": "https://finance.yahoo.com/m/fd02108e-3df5-37e3-bbd6-37c805216718/telix-opens.html", "source_name": "Pharmaceutical Technology", "published_at": "2026-07-16T10:12:11+00:00", "published_display": "16 Jul 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/telix-opens-australian-first-facility-003000120.html", "source_name": "PR Newswire", "published_at": "2026-07-16T00:30:00+00:00", "published_display": "16 Jul 2026 00:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Reports First Patients Dosing in Prostate Cancer Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/telix-reports-first-patients-dosing-205830799.html", "source_name": "MT Newswires", "published_at": "2026-07-15T20:58:30+00:00", "published_display": "15 Jul 2026 20:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer", "summary": "Telix Pharmaceuticals Limited and St Vincent's Hospital have dosed the first patients in the OPTIMAL-e trial for metastatic hormone-sensitive prostate cancer (mHSPC). The Phase 2 study evaluates TLX597-Tx, a next-generation PSMA-targeting radioligand therapy, in combination with ", "url": "https://en.prnasia.com/releases/apac/first-patients-dosed-in-optimal-e-trial-for-earlier-stage-prostate-cancer-540833.shtml", "source_name": "PR Newswire Asia", "published_at": "2026-07-15T20:44:39", "published_display": "15 Jul 2026 20:44", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Tests Targeted Therapy Earlier in Metastatic Prostate Cancer", "summary": "Telix Pharmaceuticals, in collaboration with St Vincent\u2019s Hospital Sydney, has dosed the first patients in its Phase 2 OPTIMAL-e trial for metastatic hormone-sensitive prostate cancer (mHSPC). The trial evaluates TLX597-Tx, a PSMA-targeting radioligand therapy, in combination wit", "url": "https://www.stocktitan.net/news/TLX/first-patients-dosed-in-optimal-e-trial-for-earlier-stage-prostate-tjvanx6rkkyg.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:44:39", "published_display": "15 Jul 2026 20:44", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What's Driving Telix's Latest FDA Resubmission for Pixclara\u00ae", "summary": "Telix Pharmaceuticals has resubmitted its New Drug Application (NDA) for Pixclara\u00ae (TLX101-Px), a PET imaging agent for brain cancer, to the U.S. FDA, addressing previous data requests. The drug holds Orphan Drug and Fast Track designations, indicating an urgent medical need and ", "url": "https://www.kavout.com/market-lens/what-s-driving-telix-s-latest-fda-resubmission-for-pixclara", "source_name": "Kavout | AI", "published_at": "2026-07-11T10:42:23", "published_display": "11 Jul 2026 10:42", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Class Action Lawsuit Alert: Levi & Korsinsky Reminds Telix Pharma", "summary": "Levi & Korsinsky, LLP has announced a securities class action lawsuit against Telix Pharmaceuticals Ltd. (NASDAQ: TLX). The lawsuit alleges that Telix Pharmaceuticals made false and misleading statements about the progress of its prostate cancer therapeutic candidates and the qua", "url": "https://www.natlawreview.com/press-releases/class-action-lawsuit-alert-levi-korsinsky-reminds-telix-pharmaceuticals-ltd", "source_name": "The National Law Review", "published_at": "2026-07-11T10:39:57", "published_display": "11 Jul 2026 10:39", "sentiment": "negative", "sentiment_pct": 8, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Telix Pharmaceuticals (ASX:TLX) Trading Near its 52-Week High or Low?", "summary": "Telix Pharmaceuticals (ASX:TLX) shares increased by 2.17% to AUD 16.940, closing at its intraday high during the latest trading session. The company's market capitalization reached approximately AUD 5.62 billion, though trading volume was below average. Despite the gain, the stoc", "url": "https://kalkine.com.au/news/healthcare/is-telix-pharmaceuticals-asxtlx-trading-near-its-52-week-high-or-low", "source_name": "Kalkine", "published_at": "2026-07-09T13:48:50", "published_display": "09 Jul 2026 13:48", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals strengthens radiopharmaceutical pipeline as oncology demand grows", "summary": "Telix Pharmaceuticals Ltd is expanding its portfolio of targeted radiopharmaceuticals to meet the increasing global demand for oncology treatment. The Australian company focuses on precision cancer imaging and therapy, particularly with radiolabeled molecules, and has a diversifi", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/telix-pharmaceuticals-strengthens-radiopharmaceutical-pipeline-as-oncology/69731607", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T11:48:50", "published_display": "09 Jul 2026 11:48", "sentiment": "positive", "sentiment_pct": 74, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals Limited Actuals & Estimates (ASX:TLX)", "summary": "This article provides an overview of Telix Pharmaceuticals Limited (ASX:TLX) financial actuals and estimates. It covers current stock price, historical performance, analyst forecasts ranging from 17.94 AUD to 31.78 AUD, and key financial metrics including market capitalization, e", "url": "https://www.tradingview.com/symbols/ASX-TLX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-07-09T09:40:29", "published_display": "09 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals Ltd updates investors as radiopharmaceutical pipeline advances", "summary": "Telix Pharmaceuticals Ltd is updating investors on its radiopharmaceutical pipeline and global expansion strategy, focusing on targeted cancer imaging and therapy. The company aims to provide more accurate diagnosis and treatment for solid tumors through its precision oncology pr", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/telix-pharmaceuticals-ltd-updates-investors-as-radiopharmaceutical/69725046", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T17:52:00", "published_display": "08 Jul 2026 17:52", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Telix Pharmaceuticals (ASX:TLX) Lifting Sentiment Across ASX Biotech Stocks?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdWIwLUp6a21QOE9EV1MzX3Qxek8zY3U1eDM2YzJhRzBhQnNXVTlaTHRqOWQzUDc0cm9XYXR4Tk8tNHBxVllKS0Q2WEptcmpKYXc3X0RrUkl5Y2FSNHpoVnJfc1p1Q283cXpHTm5wb0tWZjBMVDFteFhRSERGbDBYR252MDM2SV9wTEo3ZV9FWkNJby1GWFFUckVnMVdwVXhjdjlLV0JUMkhQTWctaUhYc2tZcjVZREZkTVp5VnZBQUdpTmc?oc=5", "source_name": "Kalkine Media", "published_at": "2026-07-08T08:02:00+00:00", "published_display": "08 Jul 2026 08:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals Limited (TLX): Investor Outlook Unveils 75% Upside Potential", "summary": "Telix Pharmaceuticals (TLX), an Australian biopharmaceutical company focusing on radiopharmaceuticals, is drawing significant investor interest with its promising growth and substantial upside potential. Despite current unprofitability, analysts maintain a strong buy rating, with", "url": "https://www.directorstalkinterviews.com/telix-pharmaceuticals-limited-tlx-investor-outlook-unveils-75-upside-potential/4121255604", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-06T10:25:00", "published_display": "06 Jul 2026 10:25", "sentiment": "positive", "sentiment_pct": 73, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals builds on radiopharmaceutical pipeline as investors watch oncology growth", "summary": "Telix Pharmaceuticals, an Australian radiopharmaceutical company, is expanding its oncology pipeline by developing targeted radiation therapies for cancer diagnosis and treatment. The company focuses on integrated imaging and therapy (theranostics) for various cancers and employs", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/telix-pharmaceuticals-builds-on-radiopharmaceutical-pipeline-as-investors/69699167", "source_name": "AD HOC NEWS", "published_at": "2026-07-05T17:39:44", "published_display": "05 Jul 2026 17:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals (ASX:TLX) Clears FDA Trial Step, Does It Look Fairly Valued?", "summary": "Telix Pharmaceuticals (ASX:TLX) recently confirmed with the FDA that safety data from its ProstACT Global Phase 3 trial supports advancing TLX591-Tx. After a significant stock appreciation, analysts estimate the company is still undervalued, though it faces risks like an SEC subp", "url": "https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-clears-fda-trial-step-does-it-l", "source_name": "Simply Wall Street", "published_at": "2026-07-03T20:09:40", "published_display": "03 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA backs Telix (NASDAQ: TLX) ProstACT Global Phase 3 trial design", "summary": "Telix Pharmaceuticals has announced FDA alignment regarding its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer. The FDA confirmed that Part 1 safety data are sufficient to advance to Part 2 in the U.S. and agreed with the clinical p", "url": "https://www.stocktitan.net/sec-filings/TLX/6-k-telix-pharmaceuticals-ltd-current-report-foreign-issuer-1df2b6942b3e.html", "source_name": "Stock Titan", "published_at": "2026-07-03T09:42:13", "published_display": "03 Jul 2026 09:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals Ltd (TLX.AU) Short interest going down consistently!", "summary": "The article highlights that Telix Pharmaceuticals Ltd (TLX.AU) is experiencing a consistent decrease in short interest. This information was posted by a user named 152291402 on the moomoo Community platform. The post suggests a positive sentiment regarding the stock, as reduced s", "url": "https://www.moomoo.com/community/feed/telix-pharmaceuticals-ltd-tlx-au-short-interest-going-down-consistently-116853689155590", "source_name": "Moomoo", "published_at": "2026-07-03T07:41:15", "published_display": "03 Jul 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did You Lose Money on Telix Pharmaceuticals Ltd. (TLX)? Levi & Korsinsky Urges Investors to Act Before January 9, 2026", "summary": "Levi & Korsinsky, LLP has filed a securities class action lawsuit against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) on behalf of investors who purchased its securities. The lawsuit alleges that Telix Pharmaceuticals made false and misleading statements about the progress of its pr", "url": "https://natlawreview.com/press-releases/did-you-lose-money-telix-pharmaceuticals-ltd-tlx-levi-korsinsky-urges", "source_name": "The National Law Review", "published_at": "2026-07-03T01:09:40", "published_display": "03 Jul 2026 01:09", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals : FDA Alignment to Advance ProstACT Global Phase 3 Trial", "summary": "Telix Pharmaceuticals announced alignment with the U.S. FDA to advance the ProstACT Global Phase 3 trial for its therapeutic candidate TLX591-Tx in metastatic castration-resistant prostate cancer. The FDA confirmed that initial safety data is sufficient to allow progression into ", "url": "https://www.marketscreener.com/news/telix-pharmaceuticals-fda-alignment-to-advance-prostact-global-phase-3-trial-ce7f5fd2dc8ff22d", "source_name": "www.marketscreener.com", "published_at": "2026-07-02T20:09:40", "published_display": "02 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Alignment to Advance ProstACT Global Phase 3 Trial", "summary": "Telix Pharmaceuticals announced a successful Type B meeting with the FDA, securing alignment to advance Part 2 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer into the U.S. The FDA approved the safety data from Part 1 and agre", "url": "https://www.sahmcapital.com/news/content/fda-alignment-to-advance-prostact-global-phase-3-trial-2026-07-02", "source_name": "Sahm", "published_at": "2026-07-02T09:11:10", "published_display": "02 Jul 2026 09:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals Says FDA Clears Path to Advance Phase 3 Study of Prostate Cancer Drug Candidate", "summary": "Telix Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for TLX250-CDx. This clearance allows Telix to proceed with a global Phase 3 study of the prostate cancer imaging agent. The study aims to e", "url": "https://www.moomoo.com/news/post/72380368/telix-pharmaceuticals-says-fda-clears-path-to-advance-phase-3?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-02T08:10:57", "published_display": "02 Jul 2026 08:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals aligns with FDA on Phase 3 trial", "summary": "Telix Pharmaceuticals has aligned with the US FDA on its global Phase 3 clinical trial protocol for prostate cancer, following a successful 36-patient safety study. This agreement allows the company to expand recruitment into the US market, with its shares experiencing upward tra", "url": "https://grafa.com/en/news/australia/telix-pharmaceuticals-aligns-with-fda-on-phase-3-trial", "source_name": "grafa.com", "published_at": "2026-07-02T04:09:32", "published_display": "02 Jul 2026 04:09", "sentiment": "positive", "sentiment_pct": 93, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix clears FDA protocol review for prostate cancer trial expansion", "summary": "Telix Pharmaceuticals announced that the U.S. FDA has agreed for its ProstACT Global Phase 3 trial to advance to Part 2 in the United States, based on sufficient safety data from Part 1. The FDA also aligned with Telix on the clinical protocol, statistical analysis plan, and safe", "url": "https://www.stocktitan.net/news/TLX/fda-alignment-to-advance-prost-act-global-phase-3-bx256lh1yv8d.html", "source_name": "Stock Titan", "published_at": "2026-07-02T04:09:32", "published_display": "02 Jul 2026 04:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals Secures FDA Alignment for Key Prostate Cancer Trial in U.S.", "summary": "Telix Pharmaceuticals has secured alignment with the FDA to advance Part 2 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer in the U.S. The FDA reviewed safety and dosimetry data from Part 1 and the Part 2 protocol design, conf", "url": "https://www.sharecafe.com.au/2026/07/02/telix-pharmaceuticals-secures-fda-alignment-for-key-prostate-cancer-trial-in-u-s/", "source_name": "Sharecafe", "published_at": "2026-07-02T00:09:32", "published_display": "02 Jul 2026 00:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Telix (ASX:TLX) Using Vertical Integration To Quietly Redefine Its Radiopharmaceutical Moat?", "summary": "Telix Pharmaceuticals is leveraging vertical integration and strategic deal-making in manufacturing and distribution to strengthen its position in the radiopharmaceutical market for precision oncology. While the company projects significant revenue and earnings growth by 2029, in", "url": "https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/is-telix-asxtlx-using-vertical-integration-to-quietly-redefi", "source_name": "Simply Wall Street", "published_at": "2026-07-01T11:40:49", "published_display": "01 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Class Action Lawsuit Filed Against Telix Pharmaceuticals Ltd. (TLX) - Recover Losses - Contact Levi & Korsinsky Before January 9, 2026", "summary": "A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (TLX) on behalf of investors who purchased securities between February 21, 2025, and August 28, 2025. The lawsuit alleges that Telix Pharmaceuticals made false and misleading statements regarding the progres", "url": "https://www.natlawreview.com/press-releases/class-action-lawsuit-filed-against-telix-pharmaceuticals-ltd-tlx-recover", "source_name": "The National Law Review", "published_at": "2026-07-01T09:09:32", "published_display": "01 Jul 2026 09:09", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals Stock Leads 3 Australian Growth Picks With High Insider Ownership", "summary": "This article highlights three Australian growth stocks with high insider ownership: Telix Pharmaceuticals (ASX:TLX), Lindian Resources (ASX:LIN), and GemLife Communities Group (ASX:GLF). Telix Pharmaceuticals is noted for its commercial-stage biopharmaceutical operations and canc", "url": "https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-stock-leads-3-australian-growth-picks", "source_name": "Simply Wall Street", "published_at": "2026-06-30T05:10:58", "published_display": "30 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ChartWatch ASX Scans: Pro Medicus, Life360, Telix Pharmaceuticals, Zip Co, Global X Cybersecurity ETF, Lindian Resources", "summary": "This article provides daily ASX scans based on Carl Capolingua's trend following technical analysis methodology, highlighting interesting uptrends and downtrends. It lists companies like Life360, Pro Medicus, and Telix Pharmaceuticals in uptrends, and Autosports and Bellevue Gold", "url": "https://www.marketindex.com.au/news/chartwatch-asx-scans-pro-medicus-life360-telix-pharmaceuticals-zip-co-global-x-cybersecurity-etf-lindian-resources", "source_name": "Market Index", "published_at": "2026-06-30T02:10:58", "published_display": "30 Jun 2026 02:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fast Growing Australian Stocks With High Insider Ownership Worth A Closer Look", "summary": "This article highlights three fast-growing Australian stocks with high insider ownership: Telix Pharmaceuticals (ASX:TLX), Lindian Resources (ASX:LIN), and GemLife Communities Group (ASX:GLF). It discusses their business models, market performance, growth prospects, and associate", "url": "https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/fast-growing-australian-stocks-with-high-insider-ownership-w", "source_name": "Simply Wall Street", "published_at": "2026-06-29T01:41:08", "published_display": "29 Jun 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals Stock And Two Australian Insider Led Growth Plays", "summary": "This article examines Telix Pharmaceuticals, Lindian Resources, and GemLife Communities Group, highlighting them as growth plays led by insider ownership in Australia. Telix Pharmaceuticals is noted for its commercial radiopharmaceutical sales and oncology pipeline, Lindian Resou", "url": "https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-stock-and-two-australian-insider-led-g/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-27T14:11:07", "published_display": "27 Jun 2026 14:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals clear FDA panel milestone, shares react in oncology sector context", "summary": "Telix Pharmaceuticals (AU000000TLX2) is gaining investor attention following its progress in the FDA regulatory pathway for its radiopharmaceutical pipeline, particularly for prostate cancer imaging and treatment. The company operates in a competitive oncology sector alongside ma", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/telix-pharmaceuticals-clear-fda-panel-milestone-shares-react-in-oncology/69634398", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-26T15:11:00", "published_display": "26 Jun 2026 15:11", "sentiment": "positive", "sentiment_pct": 69, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals (ASX:TLX): Is This Biotech Growth Story Still Intact?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQUDhicmc1NDJiWGlHXy00NEEtMzI4WklXWG9aaVVqUkFXRjg3V3BTSTZJRUVzcTJIRmVQSVFyZUw3OFpRY2Q4dzBVVjROSUNTY1dobm5hUVg5TlNsZUU5T1dlLXhDalM3RTB4N2Y5d3Fwc2FQQmZZQUQ3T0JwMnZWRXpyWENYY1VpUndzcjc4SjdUU3NUcEozNnQ2YkhLZEkwMTd3bUtyZGcwVkdxQWc?oc=5", "source_name": "Kalkine", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/telix-educational-webinar-neuro-oncology-214000146.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T21:40:00+00:00", "published_display": "22 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix webinar spotlights glioblastoma care and theranostics next week", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNREVKMHZSSk14VjVTVEpDZ2U2Ql9RZGpZbVhkVzhBeXg2WjQ1dzB5Q25WVzdjTnllbzZQM3Z2Mmx3NHk2ZW1UbXc1REVnM2lZSVpjbFNLRjR3S25vSDdybVhZN1RuSk1xZG5TLUV1VTN3NzVVYVN5S3puX09qWXNFN0xtZVk4dlhsYlllWl9raXc2NVctci1PenNabFdQU19OSGdaYWFDajhBQ01McWpYd0VUQ3VMQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals (TLX), United Imaging Healthcare Form Strategic Theranostics Research Partnership", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/telix-pharmaceuticals-tlx-united-imaging-193832635.html", "source_name": "Insider Monkey", "published_at": "2026-06-17T19:38:32+00:00", "published_display": "17 Jun 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals (ASX:TLX): Is This ASX Biotech Stock a Buy Opportunity", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPcEwzaFlTZ19yUkx2OVJMYVlNQzdtSVNWZTdsLWxTV3dMNk5WTkFETlNoaDFGaXFZSjR2SWFYN2JIV3FkUG5WOWhmbzVGalZVbTJIdmlhdWwyQWF5QlBmYjZuUUdBX0Z5ZEsyVkROTmpFX0xtdGU1bUhOWXpoRjNRT2FieGlFOWI1RF9FVFVwMkxja2pmLWdUN2M4SDhac2FLeW1UY1hrRXZZMjRQ?oc=5", "source_name": "Kalkine", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_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?oc=5", "source_name": "The Manila Times", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals (TLX) furnishes AGM addresses, presentation and results via Form 6-K", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNcHBEY3NPTllmWlJ6TzdhOFNJQ2Vyc2NWVDBYUVpleUdJTkFwVzB6YjVwd2JZUGhlNHRNVkpSZC1RSWVxazFiMmR6U011ZEk0bFNFek9lZ19ZbXcxM25vZVBSUGgtaWhuRGg5YlE5dnVxMGoyMmkzOUthYVAyejIzeXAtb2F6aXRfNU9ocW9RU0VmZlAwWnZhdE52UkN1bGFEZWd5YmxXRTY5Q0JZYVl5c0FST3h1NjNKMzczUg?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Telix Pharmaceuticals Limited (TLX) Stock Analysis: Unpacking A 103.67% Potential Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxNc1dnMGJLQXFPMEtmaldLOE03Z3kxdHNuME9DSnpDSmdMcHRGWlBRQTZnRjBMZkYtODlyRGZfX3owSURIdFVzaEg0djVXSVMtVzhNNW94LW5PZEVBLWFwYzFON3k5bXo0ajN5SGpQYnc5UFJUNDVfYnR3WXlPTFJLQXZvcTJjSG83RUdaX0puMG0tTng0VUYyTm9OOUNadVFGbWh2UC1ZUUtpdkdZRnNKS21fdjBXWXBpOW00T3pVbk1pa19DNlU1MDl6QmktY19q?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Insider Buying: Telix Pharmaceuticals Co-Founder Bought US$997k Of Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNUUFWRmNJSFlwMWF3R0h6UmRXOWFQLUl1aklqLW5ud09URm1TelYwLUY4bHlNRkNBZzNNcjc3ZjNIM0lsQllySFUwRVUzczZBeHk3TUdwZm1iUEZMMUZWeVIyNHBwV0NPRGRKbWxZVy1ieFdkTWF2VVRyejc4dXVxTUI3dDJqVUVPLWlFMllJNFA3cXo3dTBhR3U1cG9tQzhaZlhsUmVqNA?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals (TLX): How Are Its Clinical Programs Doing?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOYkJ4eVVJQzZtaUtjSl9hcmJtVlVLU1ZHRU0zc3NJbWFZdzEwTUdGRTM4Nk1HYmtQcWZjcW5fSjlZaUp5U2d3Wk9oOS1IdjZmSTgwMHZ1bDdRNFJCSDV5dS1TcV9fZjNCVHBwaUswaktybzJuSkljdmcxRjF4T1p4dUxRV3AyV1NxVmp5QTFBWWUtOFB4X2ZVaWUzbEtVdGRKY0s4dzJXbE9Rc0gyV3BBZ0VB?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Telix\u2019s Phase 3 prostate cancer study gets a late-breaking ASCO slot", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNUXFtdlFsOXNiWU1aUzdxOW00aFR4OWloWTlKMk1aQjBRLUVVZF9fSHVPaldaMHFUb3VIajU3M2dUQTVQcER5SGFYdDBESUtmVzRvNlV3eGRSTGdIMnBDbm1iR2loY2RBYUFaVlpaTHh4S21vdzkwTnJWaTRmT2ZZZDhYR2hLT2xBRVdFUUhPd2ZBUEowN1BpQUpsbEZlXzd6Y3FQRHRRU1Y0SWFCc0R4V3ZJZld6ZjBEUkRjaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Telix Pharmaceuticals Shares Dip as Convertible Bond Expansion Triggers Dilution Concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNTmI5M2FSaGdEeEttcUlLbHZMOTBTbzJ4REZpalRKS09HLVY1ZmNNcHhpc3VjQ1U4T3FCaWJoeXJxVnZ3TF9ocGNtTXJvdHR4X2Fha3RPM2taOHNQeHZCZFBsdzhKRUxaU0tqSnhQYk1JODZad3ozazdoanpjd0pIUVpsb25vbGZVYTVtSUt5MHo5eGxDenU0UDN4X2RmNEYyRGFZUl8zdUdUTDIzTTgzOUJDbjdRVklKeGc?oc=5", "source_name": "thebull.com.au", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Refinances Convertible Bonds", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPd1RsZGZwWF9pR3pJUDVlZHBFLTMxUk1WTHgxZDBhT0pNNnFmc1FlTElKTGFFQ0hpWjlVSFNZV2xRTllxU3pfWmcwM3VvcEJDT0pEQUZHR2pLMkdDWGlLUnRWb3k5ZG96Q2I3dFdnb0l3TVhPM2s5MzdURTlNZlBEX2R2SWhkMm12Q29NOUZZbzhuMXJ0?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Recent Share Price Moves", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPWTh2Y3hwd1VOVXVONlhleVA2YzZROVJYWFJKaUZMcHZ1bVhNYVFFVldoVWptdno2VDluREJrLTlNX0VmbUpCVG5BaWduMzVuT3IzR2hETFhuRTAzRzF1bFRMTm1tdnlhcGJvb3FLaW94d3R1eXFkaUQ5NWFVcm9BY180d25FaW9sbzVFSk1QRlZBeE45ZldsOEg0dXotMDRw?oc=5", "source_name": "Market source", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds \u2013 Company Announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOZ0tPVTRhU1J6ejJlRjJtOWF5Mnh0WUs2UUROVHVobml3Z29CdkpXUFNER18ycFNBeU5rUVdIUEpmbUtfb3pjLUxhdzJQcXJGQXhTd0gwTEJhSlpsZGdFVzlhTFhleVRGTDNiNG5jZHRPZmJoWlRTaFVNLVJKLU5DVkk2OVdCTFFrel9wWFA3Tmp6bzhpQ0hxQw?oc=5", "source_name": "Financial Times", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix share price leaping higher today on $3 billion US news", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQRS12RTVQVW1Sa1NObUEyNFdDNWtaV0dyX1hadF8tTEE2c1IwYjdNS2tmSmg5YXJoUVB4Q0luSlJ3LU1zNnJYTVFjQmNUZVdoQkpfSHYwMWpja2hfUU8wWE9kR2cyZnJhcGRvaWVkREVOY3VNN1FlRU52TmJxRFhYWk9aNkxldHNfc2ZCbWxwa2RQSE1vb0JoaE9MOA?oc=5", "source_name": "The Motley Fool Australia", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals Share Hit 2026 High as FDA Accepts Brain Cancer Imaging Drug Application", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNdHZSYlVNSjRqcjVIc2JhS3FxR2xhSW92YkpCSzFBaUtZSkFSUkdwTVdZU1hGTzQ3X0Rvb3pKUHc3VVl6Njk5TEhvTjByMi1OcmJaMXRuQ0RNeE5yWnlaTHVlTmRYVXZ4TUZrXzM2bDU0a21ybkJDa0dGRGJYV2otbVM2WWtRYmxMcUpCd1VCNTZtMVY3cHl2Qms3b2dUTEFxa0xWUVREcXR0UXRKWkcySTNVZ3BlNHNud204UlFCbWg?oc=5", "source_name": "thebull.com.au", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix lines up next chair with board seat for biotech veteran David Gill", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNdXk0SGdEZndJa1VJMUNaeXBIcE1sTy1LR1lXMFhPZUNOQUpRdnFYZE1DYTF3QkxxcGRGTUlKQWFkYTYwaFhYaUZERU41SFIxblNWOUZFNm03NnJ2ajJOTWJuVVhQRmNtcjRwVDhtbGRzMFJOd0ltMmlLM1FxWEJfYWVzWTE2LXFpQm5pLUxZekE5NzFHdDYzTGxHcnM?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Telix Pharmaceuticals (ASX:TLX) Stock Jumps 5.89%: FDA Resubmission Fuels Investor Optimism", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQVmdtLTN3bnBvNTRQQnpoX2dBU0dNS0FtV2ZpWHFrMV9ZVFByN0F1RGZPcU5zNWtJSTQ1cDNDalFQQm5SWlVMSWFfU2ZVUk5UR2RtQXVINzZHMklZa0FMVHQxNVkxdnlvU21xeDViZ0FYcU5naVNkUVNnSG9hUlB4WjJ6S2pJNGpQMDRaa2lDc01YVkRiVDRtbTlPM0p4NWgyT1FiRk55ODJ1ODNHQnYxNmxRYWM2d3VELUFoU0xJc1BPUnhz?oc=5", "source_name": "Kalkine", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara\u00ae) Brain Cancer Imaging Candidate", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNUEU4cmVQbnRQcWRWSHRKdWEwUFpYVkEtQkdlbm94Q19rSWQwcERUdThOZXBacXZ1TEJsc0hSQmFNUFRLTVRKaVlSTEw5Wm5KYk9XMVFZTk9SbnBxS3NjVGEyd0cyZm1oMkJ0VHFzbC1wRUZmM1FxWmxNMkFiaUozMXZoaFN4eGFRcW5OVms5TzV4eDJidE14STJyTU1XVUlLTGVKa2x0OGRQTS1URS1oTldjMFlNQTI2djdTNy0yMlo0VF9DMlptbFAyRWZPVm5rQm5EVWp1NVN2UUkw?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock of the day: Telix Pharmaceuticals", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQOUUyMGZrcVF2YU9QVGhvMk1TaW0yTVhMODVEeG5CaU1IMUVTSXJvUEt0TnM2Y2hyYWhOeFdNckZpcWdRcWxyeVNxREVzbS1qc0R3aDhXcjgzVTY1cFlKcDVXNGoxSVFiMkRiVFU2ZkZxemdfNHhtWE54S2tVWHN5VVkzc1NNenFLNEp5R0oweUQtLUZQQkp3?oc=5", "source_name": "ig.com", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Telix opens radiopharmaceutical facility in Australia for cancer treatment", "summary": "", "url": "https://finance.yahoo.com/m/fd02108e-3df5-37e3-bbd6-37c805216718/telix-opens.html", "source_name": "Pharmaceutical Technology", "published_at": "2026-07-16T10:12:11+00:00", "published_display": "16 Jul 2026 10:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/telix-opens-australian-first-facility-003000120.html", "source_name": "PR Newswire", "published_at": "2026-07-16T00:30:00+00:00", "published_display": "16 Jul 2026 00:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Reports First Patients Dosing in Prostate Cancer Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/telix-reports-first-patients-dosing-205830799.html", "source_name": "MT Newswires", "published_at": "2026-07-15T20:58:30+00:00", "published_display": "15 Jul 2026 20:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer", "summary": "Telix Pharmaceuticals Limited and St Vincent's Hospital have dosed the first patients in the OPTIMAL-e trial for metastatic hormone-sensitive prostate cancer (mHSPC). The Phase 2 study evaluates TLX597-Tx, a next-generation PSMA-targeting radioligand therapy, in combination with ", "url": "https://en.prnasia.com/releases/apac/first-patients-dosed-in-optimal-e-trial-for-earlier-stage-prostate-cancer-540833.shtml", "source_name": "PR Newswire Asia", "published_at": "2026-07-15T20:44:39", "published_display": "15 Jul 2026 20:44", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Tests Targeted Therapy Earlier in Metastatic Prostate Cancer", "summary": "Telix Pharmaceuticals, in collaboration with St Vincent\u2019s Hospital Sydney, has dosed the first patients in its Phase 2 OPTIMAL-e trial for metastatic hormone-sensitive prostate cancer (mHSPC). The trial evaluates TLX597-Tx, a PSMA-targeting radioligand therapy, in combination wit", "url": "https://www.stocktitan.net/news/TLX/first-patients-dosed-in-optimal-e-trial-for-earlier-stage-prostate-tjvanx6rkkyg.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:44:39", "published_display": "15 Jul 2026 20:44", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Driving Telix's Latest FDA Resubmission for Pixclara\u00ae", "summary": "Telix Pharmaceuticals has resubmitted its New Drug Application (NDA) for Pixclara\u00ae (TLX101-Px), a PET imaging agent for brain cancer, to the U.S. FDA, addressing previous data requests. The drug holds Orphan Drug and Fast Track designations, indicating an urgent medical need and ", "url": "https://www.kavout.com/market-lens/what-s-driving-telix-s-latest-fda-resubmission-for-pixclara", "source_name": "Kavout | AI", "published_at": "2026-07-11T10:42:23", "published_display": "11 Jul 2026 10:42", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Class Action Lawsuit Alert: Levi & Korsinsky Reminds Telix Pharma", "summary": "Levi & Korsinsky, LLP has announced a securities class action lawsuit against Telix Pharmaceuticals Ltd. (NASDAQ: TLX). The lawsuit alleges that Telix Pharmaceuticals made false and misleading statements about the progress of its prostate cancer therapeutic candidates and the qua", "url": "https://www.natlawreview.com/press-releases/class-action-lawsuit-alert-levi-korsinsky-reminds-telix-pharmaceuticals-ltd", "source_name": "The National Law Review", "published_at": "2026-07-11T10:39:57", "published_display": "11 Jul 2026 10:39", "sentiment": "negative", "sentiment_pct": 8, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Telix Pharmaceuticals (ASX:TLX) Trading Near its 52-Week High or Low?", "summary": "Telix Pharmaceuticals (ASX:TLX) shares increased by 2.17% to AUD 16.940, closing at its intraday high during the latest trading session. The company's market capitalization reached approximately AUD 5.62 billion, though trading volume was below average. Despite the gain, the stoc", "url": "https://kalkine.com.au/news/healthcare/is-telix-pharmaceuticals-asxtlx-trading-near-its-52-week-high-or-low", "source_name": "Kalkine", "published_at": "2026-07-09T13:48:50", "published_display": "09 Jul 2026 13:48", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals strengthens radiopharmaceutical pipeline as oncology demand grows", "summary": "Telix Pharmaceuticals Ltd is expanding its portfolio of targeted radiopharmaceuticals to meet the increasing global demand for oncology treatment. The Australian company focuses on precision cancer imaging and therapy, particularly with radiolabeled molecules, and has a diversifi", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/telix-pharmaceuticals-strengthens-radiopharmaceutical-pipeline-as-oncology/69731607", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-09T11:48:50", "published_display": "09 Jul 2026 11:48", "sentiment": "positive", "sentiment_pct": 74, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals Limited Actuals & Estimates (ASX:TLX)", "summary": "This article provides an overview of Telix Pharmaceuticals Limited (ASX:TLX) financial actuals and estimates. It covers current stock price, historical performance, analyst forecasts ranging from 17.94 AUD to 31.78 AUD, and key financial metrics including market capitalization, e", "url": "https://www.tradingview.com/symbols/ASX-TLX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-07-09T09:40:29", "published_display": "09 Jul 2026 09:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals Ltd updates investors as radiopharmaceutical pipeline advances", "summary": "Telix Pharmaceuticals Ltd is updating investors on its radiopharmaceutical pipeline and global expansion strategy, focusing on targeted cancer imaging and therapy. The company aims to provide more accurate diagnosis and treatment for solid tumors through its precision oncology pr", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/telix-pharmaceuticals-ltd-updates-investors-as-radiopharmaceutical/69725046", "source_name": "AD HOC NEWS", "published_at": "2026-07-08T17:52:00", "published_display": "08 Jul 2026 17:52", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Telix Pharmaceuticals (ASX:TLX) Lifting Sentiment Across ASX Biotech Stocks?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOdWIwLUp6a21QOE9EV1MzX3Qxek8zY3U1eDM2YzJhRzBhQnNXVTlaTHRqOWQzUDc0cm9XYXR4Tk8tNHBxVllKS0Q2WEptcmpKYXc3X0RrUkl5Y2FSNHpoVnJfc1p1Q283cXpHTm5wb0tWZjBMVDFteFhRSERGbDBYR252MDM2SV9wTEo3ZV9FWkNJby1GWFFUckVnMVdwVXhjdjlLV0JUMkhQTWctaUhYc2tZcjVZREZkTVp5VnZBQUdpTmc?oc=5", "source_name": "Kalkine Media", "published_at": "2026-07-08T08:02:00+00:00", "published_display": "08 Jul 2026 08:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals Limited (TLX): Investor Outlook Unveils 75% Upside Potential", "summary": "Telix Pharmaceuticals (TLX), an Australian biopharmaceutical company focusing on radiopharmaceuticals, is drawing significant investor interest with its promising growth and substantial upside potential. Despite current unprofitability, analysts maintain a strong buy rating, with", "url": "https://www.directorstalkinterviews.com/telix-pharmaceuticals-limited-tlx-investor-outlook-unveils-75-upside-potential/4121255604", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-06T10:25:00", "published_display": "06 Jul 2026 10:25", "sentiment": "positive", "sentiment_pct": 73, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals builds on radiopharmaceutical pipeline as investors watch oncology growth", "summary": "Telix Pharmaceuticals, an Australian radiopharmaceutical company, is expanding its oncology pipeline by developing targeted radiation therapies for cancer diagnosis and treatment. The company focuses on integrated imaging and therapy (theranostics) for various cancers and employs", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/telix-pharmaceuticals-builds-on-radiopharmaceutical-pipeline-as-investors/69699167", "source_name": "AD HOC NEWS", "published_at": "2026-07-05T17:39:44", "published_display": "05 Jul 2026 17:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals (ASX:TLX) Clears FDA Trial Step, Does It Look Fairly Valued?", "summary": "Telix Pharmaceuticals (ASX:TLX) recently confirmed with the FDA that safety data from its ProstACT Global Phase 3 trial supports advancing TLX591-Tx. After a significant stock appreciation, analysts estimate the company is still undervalued, though it faces risks like an SEC subp", "url": "https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-clears-fda-trial-step-does-it-l", "source_name": "Simply Wall Street", "published_at": "2026-07-03T20:09:40", "published_display": "03 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA backs Telix (NASDAQ: TLX) ProstACT Global Phase 3 trial design", "summary": "Telix Pharmaceuticals has announced FDA alignment regarding its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer. The FDA confirmed that Part 1 safety data are sufficient to advance to Part 2 in the U.S. and agreed with the clinical p", "url": "https://www.stocktitan.net/sec-filings/TLX/6-k-telix-pharmaceuticals-ltd-current-report-foreign-issuer-1df2b6942b3e.html", "source_name": "Stock Titan", "published_at": "2026-07-03T09:42:13", "published_display": "03 Jul 2026 09:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals Ltd (TLX.AU) Short interest going down consistently!", "summary": "The article highlights that Telix Pharmaceuticals Ltd (TLX.AU) is experiencing a consistent decrease in short interest. This information was posted by a user named 152291402 on the moomoo Community platform. The post suggests a positive sentiment regarding the stock, as reduced s", "url": "https://www.moomoo.com/community/feed/telix-pharmaceuticals-ltd-tlx-au-short-interest-going-down-consistently-116853689155590", "source_name": "Moomoo", "published_at": "2026-07-03T07:41:15", "published_display": "03 Jul 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did You Lose Money on Telix Pharmaceuticals Ltd. (TLX)? Levi & Korsinsky Urges Investors to Act Before January 9, 2026", "summary": "Levi & Korsinsky, LLP has filed a securities class action lawsuit against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) on behalf of investors who purchased its securities. The lawsuit alleges that Telix Pharmaceuticals made false and misleading statements about the progress of its pr", "url": "https://natlawreview.com/press-releases/did-you-lose-money-telix-pharmaceuticals-ltd-tlx-levi-korsinsky-urges", "source_name": "The National Law Review", "published_at": "2026-07-03T01:09:40", "published_display": "03 Jul 2026 01:09", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals : FDA Alignment to Advance ProstACT Global Phase 3 Trial", "summary": "Telix Pharmaceuticals announced alignment with the U.S. FDA to advance the ProstACT Global Phase 3 trial for its therapeutic candidate TLX591-Tx in metastatic castration-resistant prostate cancer. The FDA confirmed that initial safety data is sufficient to allow progression into ", "url": "https://www.marketscreener.com/news/telix-pharmaceuticals-fda-alignment-to-advance-prostact-global-phase-3-trial-ce7f5fd2dc8ff22d", "source_name": "www.marketscreener.com", "published_at": "2026-07-02T20:09:40", "published_display": "02 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Alignment to Advance ProstACT Global Phase 3 Trial", "summary": "Telix Pharmaceuticals announced a successful Type B meeting with the FDA, securing alignment to advance Part 2 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer into the U.S. The FDA approved the safety data from Part 1 and agre", "url": "https://www.sahmcapital.com/news/content/fda-alignment-to-advance-prostact-global-phase-3-trial-2026-07-02", "source_name": "Sahm", "published_at": "2026-07-02T09:11:10", "published_display": "02 Jul 2026 09:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals Says FDA Clears Path to Advance Phase 3 Study of Prostate Cancer Drug Candidate", "summary": "Telix Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for TLX250-CDx. This clearance allows Telix to proceed with a global Phase 3 study of the prostate cancer imaging agent. The study aims to e", "url": "https://www.moomoo.com/news/post/72380368/telix-pharmaceuticals-says-fda-clears-path-to-advance-phase-3?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-02T08:10:57", "published_display": "02 Jul 2026 08:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals aligns with FDA on Phase 3 trial", "summary": "Telix Pharmaceuticals has aligned with the US FDA on its global Phase 3 clinical trial protocol for prostate cancer, following a successful 36-patient safety study. This agreement allows the company to expand recruitment into the US market, with its shares experiencing upward tra", "url": "https://grafa.com/en/news/australia/telix-pharmaceuticals-aligns-with-fda-on-phase-3-trial", "source_name": "grafa.com", "published_at": "2026-07-02T04:09:32", "published_display": "02 Jul 2026 04:09", "sentiment": "positive", "sentiment_pct": 93, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix clears FDA protocol review for prostate cancer trial expansion", "summary": "Telix Pharmaceuticals announced that the U.S. FDA has agreed for its ProstACT Global Phase 3 trial to advance to Part 2 in the United States, based on sufficient safety data from Part 1. The FDA also aligned with Telix on the clinical protocol, statistical analysis plan, and safe", "url": "https://www.stocktitan.net/news/TLX/fda-alignment-to-advance-prost-act-global-phase-3-bx256lh1yv8d.html", "source_name": "Stock Titan", "published_at": "2026-07-02T04:09:32", "published_display": "02 Jul 2026 04:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals Secures FDA Alignment for Key Prostate Cancer Trial in U.S.", "summary": "Telix Pharmaceuticals has secured alignment with the FDA to advance Part 2 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer in the U.S. The FDA reviewed safety and dosimetry data from Part 1 and the Part 2 protocol design, conf", "url": "https://www.sharecafe.com.au/2026/07/02/telix-pharmaceuticals-secures-fda-alignment-for-key-prostate-cancer-trial-in-u-s/", "source_name": "Sharecafe", "published_at": "2026-07-02T00:09:32", "published_display": "02 Jul 2026 00:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Telix (ASX:TLX) Using Vertical Integration To Quietly Redefine Its Radiopharmaceutical Moat?", "summary": "Telix Pharmaceuticals is leveraging vertical integration and strategic deal-making in manufacturing and distribution to strengthen its position in the radiopharmaceutical market for precision oncology. While the company projects significant revenue and earnings growth by 2029, in", "url": "https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/is-telix-asxtlx-using-vertical-integration-to-quietly-redefi", "source_name": "Simply Wall Street", "published_at": "2026-07-01T11:40:49", "published_display": "01 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Class Action Lawsuit Filed Against Telix Pharmaceuticals Ltd. (TLX) - Recover Losses - Contact Levi & Korsinsky Before January 9, 2026", "summary": "A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (TLX) on behalf of investors who purchased securities between February 21, 2025, and August 28, 2025. The lawsuit alleges that Telix Pharmaceuticals made false and misleading statements regarding the progres", "url": "https://www.natlawreview.com/press-releases/class-action-lawsuit-filed-against-telix-pharmaceuticals-ltd-tlx-recover", "source_name": "The National Law Review", "published_at": "2026-07-01T09:09:32", "published_display": "01 Jul 2026 09:09", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals Stock Leads 3 Australian Growth Picks With High Insider Ownership", "summary": "This article highlights three Australian growth stocks with high insider ownership: Telix Pharmaceuticals (ASX:TLX), Lindian Resources (ASX:LIN), and GemLife Communities Group (ASX:GLF). Telix Pharmaceuticals is noted for its commercial-stage biopharmaceutical operations and canc", "url": "https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-stock-leads-3-australian-growth-picks", "source_name": "Simply Wall Street", "published_at": "2026-06-30T05:10:58", "published_display": "30 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ChartWatch ASX Scans: Pro Medicus, Life360, Telix Pharmaceuticals, Zip Co, Global X Cybersecurity ETF, Lindian Resources", "summary": "This article provides daily ASX scans based on Carl Capolingua's trend following technical analysis methodology, highlighting interesting uptrends and downtrends. It lists companies like Life360, Pro Medicus, and Telix Pharmaceuticals in uptrends, and Autosports and Bellevue Gold", "url": "https://www.marketindex.com.au/news/chartwatch-asx-scans-pro-medicus-life360-telix-pharmaceuticals-zip-co-global-x-cybersecurity-etf-lindian-resources", "source_name": "Market Index", "published_at": "2026-06-30T02:10:58", "published_display": "30 Jun 2026 02:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fast Growing Australian Stocks With High Insider Ownership Worth A Closer Look", "summary": "This article highlights three fast-growing Australian stocks with high insider ownership: Telix Pharmaceuticals (ASX:TLX), Lindian Resources (ASX:LIN), and GemLife Communities Group (ASX:GLF). It discusses their business models, market performance, growth prospects, and associate", "url": "https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/fast-growing-australian-stocks-with-high-insider-ownership-w", "source_name": "Simply Wall Street", "published_at": "2026-06-29T01:41:08", "published_display": "29 Jun 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals Stock And Two Australian Insider Led Growth Plays", "summary": "This article examines Telix Pharmaceuticals, Lindian Resources, and GemLife Communities Group, highlighting them as growth plays led by insider ownership in Australia. Telix Pharmaceuticals is noted for its commercial radiopharmaceutical sales and oncology pipeline, Lindian Resou", "url": "https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-stock-and-two-australian-insider-led-g/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-27T14:11:07", "published_display": "27 Jun 2026 14:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals clear FDA panel milestone, shares react in oncology sector context", "summary": "Telix Pharmaceuticals (AU000000TLX2) is gaining investor attention following its progress in the FDA regulatory pathway for its radiopharmaceutical pipeline, particularly for prostate cancer imaging and treatment. The company operates in a competitive oncology sector alongside ma", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/telix-pharmaceuticals-clear-fda-panel-milestone-shares-react-in-oncology/69634398", "source_name": "Ad-hoc-news.de", "published_at": "2026-06-26T15:11:00", "published_display": "26 Jun 2026 15:11", "sentiment": "positive", "sentiment_pct": 69, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals (ASX:TLX): Is This Biotech Growth Story Still Intact?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQUDhicmc1NDJiWGlHXy00NEEtMzI4WklXWG9aaVVqUkFXRjg3V3BTSTZJRUVzcTJIRmVQSVFyZUw3OFpRY2Q4dzBVVjROSUNTY1dobm5hUVg5TlNsZUU5T1dlLXhDalM3RTB4N2Y5d3Fwc2FQQmZZQUQ3T0JwMnZWRXpyWENYY1VpUndzcjc4SjdUU3NUcEozNnQ2YkhLZEkwMTd3bUtyZGcwVkdxQWc?oc=5", "source_name": "Kalkine", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/telix-educational-webinar-neuro-oncology-214000146.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T21:40:00+00:00", "published_display": "22 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix webinar spotlights glioblastoma care and theranostics next week", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxNREVKMHZSSk14VjVTVEpDZ2U2Ql9RZGpZbVhkVzhBeXg2WjQ1dzB5Q25WVzdjTnllbzZQM3Z2Mmx3NHk2ZW1UbXc1REVnM2lZSVpjbFNLRjR3S25vSDdybVhZN1RuSk1xZG5TLUV1VTN3NzVVYVN5S3puX09qWXNFN0xtZVk4dlhsYlllWl9raXc2NVctci1PenNabFdQU19OSGdaYWFDajhBQ01McWpYd0VUQ3VMQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals (TLX), United Imaging Healthcare Form Strategic Theranostics Research Partnership", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/telix-pharmaceuticals-tlx-united-imaging-193832635.html", "source_name": "Insider Monkey", "published_at": "2026-06-17T19:38:32+00:00", "published_display": "17 Jun 2026 19:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals (ASX:TLX): Is This ASX Biotech Stock a Buy Opportunity", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPcEwzaFlTZ19yUkx2OVJMYVlNQzdtSVNWZTdsLWxTV3dMNk5WTkFETlNoaDFGaXFZSjR2SWFYN2JIV3FkUG5WOWhmbzVGalZVbTJIdmlhdWwyQWF5QlBmYjZuUUdBX0Z5ZEsyVkROTmpFX0xtdGU1bUhOWXpoRjNRT2FieGlFOWI1RF9FVFVwMkxja2pmLWdUN2M4SDhac2FLeW1UY1hrRXZZMjRQ?oc=5", "source_name": "Kalkine", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_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?oc=5", "source_name": "The Manila Times", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals (TLX) furnishes AGM addresses, presentation and results via Form 6-K", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNcHBEY3NPTllmWlJ6TzdhOFNJQ2Vyc2NWVDBYUVpleUdJTkFwVzB6YjVwd2JZUGhlNHRNVkpSZC1RSWVxazFiMmR6U011ZEk0bFNFek9lZ19ZbXcxM25vZVBSUGgtaWhuRGg5YlE5dnVxMGoyMmkzOUthYVAyejIzeXAtb2F6aXRfNU9ocW9RU0VmZlAwWnZhdE52UkN1bGFEZWd5YmxXRTY5Q0JZYVl5c0FST3h1NjNKMzczUg?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals Limited (TLX) Stock Analysis: Unpacking A 103.67% Potential Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxNc1dnMGJLQXFPMEtmaldLOE03Z3kxdHNuME9DSnpDSmdMcHRGWlBRQTZnRjBMZkYtODlyRGZfX3owSURIdFVzaEg0djVXSVMtVzhNNW94LW5PZEVBLWFwYzFON3k5bXo0ajN5SGpQYnc5UFJUNDVfYnR3WXlPTFJLQXZvcTJjSG83RUdaX0puMG0tTng0VUYyTm9OOUNadVFGbWh2UC1ZUUtpdkdZRnNKS21fdjBXWXBpOW00T3pVbk1pa19DNlU1MDl6QmktY19q?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Buying: Telix Pharmaceuticals Co-Founder Bought US$997k Of Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNUUFWRmNJSFlwMWF3R0h6UmRXOWFQLUl1aklqLW5ud09URm1TelYwLUY4bHlNRkNBZzNNcjc3ZjNIM0lsQllySFUwRVUzczZBeHk3TUdwZm1iUEZMMUZWeVIyNHBwV0NPRGRKbWxZVy1ieFdkTWF2VVRyejc4dXVxTUI3dDJqVUVPLWlFMllJNFA3cXo3dTBhR3U1cG9tQzhaZlhsUmVqNA?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals (TLX): How Are Its Clinical Programs Doing?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOYkJ4eVVJQzZtaUtjSl9hcmJtVlVLU1ZHRU0zc3NJbWFZdzEwTUdGRTM4Nk1HYmtQcWZjcW5fSjlZaUp5U2d3Wk9oOS1IdjZmSTgwMHZ1bDdRNFJCSDV5dS1TcV9fZjNCVHBwaUswaktybzJuSkljdmcxRjF4T1p4dUxRV3AyV1NxVmp5QTFBWWUtOFB4X2ZVaWUzbEtVdGRKY0s4dzJXbE9Rc0gyV3BBZ0VB?oc=5", "source_name": "Market source", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix\u2019s Phase 3 prostate cancer study gets a late-breaking ASCO slot", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNUXFtdlFsOXNiWU1aUzdxOW00aFR4OWloWTlKMk1aQjBRLUVVZF9fSHVPaldaMHFUb3VIajU3M2dUQTVQcER5SGFYdDBESUtmVzRvNlV3eGRSTGdIMnBDbm1iR2loY2RBYUFaVlpaTHh4S21vdzkwTnJWaTRmT2ZZZDhYR2hLT2xBRVdFUUhPd2ZBUEowN1BpQUpsbEZlXzd6Y3FQRHRRU1Y0SWFCc0R4V3ZJZld6ZjBEUkRjaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals Shares Dip as Convertible Bond Expansion Triggers Dilution Concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNTmI5M2FSaGdEeEttcUlLbHZMOTBTbzJ4REZpalRKS09HLVY1ZmNNcHhpc3VjQ1U4T3FCaWJoeXJxVnZ3TF9ocGNtTXJvdHR4X2Fha3RPM2taOHNQeHZCZFBsdzhKRUxaU0tqSnhQYk1JODZad3ozazdoanpjd0pIUVpsb25vbGZVYTVtSUt5MHo5eGxDenU0UDN4X2RmNEYyRGFZUl8zdUdUTDIzTTgzOUJDbjdRVklKeGc?oc=5", "source_name": "thebull.com.au", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Refinances Convertible Bonds", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPd1RsZGZwWF9pR3pJUDVlZHBFLTMxUk1WTHgxZDBhT0pNNnFmc1FlTElKTGFFQ0hpWjlVSFNZV2xRTllxU3pfWmcwM3VvcEJDT0pEQUZHR2pLMkdDWGlLUnRWb3k5ZG96Q2I3dFdnb0l3TVhPM2s5MzdURTlNZlBEX2R2SWhkMm12Q29NOUZZbzhuMXJ0?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Recent Share Price Moves", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPWTh2Y3hwd1VOVXVONlhleVA2YzZROVJYWFJKaUZMcHZ1bVhNYVFFVldoVWptdno2VDluREJrLTlNX0VmbUpCVG5BaWduMzVuT3IzR2hETFhuRTAzRzF1bFRMTm1tdnlhcGJvb3FLaW94d3R1eXFkaUQ5NWFVcm9BY180d25FaW9sbzVFSk1QRlZBeE45ZldsOEg0dXotMDRw?oc=5", "source_name": "Market source", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Successfully Prices and Upsizes US$600 Million Convertible Bonds \u2013 Company Announcement", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOZ0tPVTRhU1J6ejJlRjJtOWF5Mnh0WUs2UUROVHVobml3Z29CdkpXUFNER18ycFNBeU5rUVdIUEpmbUtfb3pjLUxhdzJQcXJGQXhTd0gwTEJhSlpsZGdFVzlhTFhleVRGTDNiNG5jZHRPZmJoWlRTaFVNLVJKLU5DVkk2OVdCTFFrel9wWFA3Tmp6bzhpQ0hxQw?oc=5", "source_name": "Financial Times", "published_at": "2026-04-14T07:00:00+00:00", "published_display": "14 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix share price leaping higher today on $3 billion US news", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQRS12RTVQVW1Sa1NObUEyNFdDNWtaV0dyX1hadF8tTEE2c1IwYjdNS2tmSmg5YXJoUVB4Q0luSlJ3LU1zNnJYTVFjQmNUZVdoQkpfSHYwMWpja2hfUU8wWE9kR2cyZnJhcGRvaWVkREVOY3VNN1FlRU52TmJxRFhYWk9aNkxldHNfc2ZCbWxwa2RQSE1vb0JoaE9MOA?oc=5", "source_name": "The Motley Fool Australia", "published_at": "2026-04-13T07:00:00+00:00", "published_display": "13 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals Share Hit 2026 High as FDA Accepts Brain Cancer Imaging Drug Application", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNdHZSYlVNSjRqcjVIc2JhS3FxR2xhSW92YkpCSzFBaUtZSkFSUkdwTVdZU1hGTzQ3X0Rvb3pKUHc3VVl6Njk5TEhvTjByMi1OcmJaMXRuQ0RNeE5yWnlaTHVlTmRYVXZ4TUZrXzM2bDU0a21ybkJDa0dGRGJYV2otbVM2WWtRYmxMcUpCd1VCNTZtMVY3cHl2Qms3b2dUTEFxa0xWUVREcXR0UXRKWkcySTNVZ3BlNHNud204UlFCbWg?oc=5", "source_name": "thebull.com.au", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix lines up next chair with board seat for biotech veteran David Gill", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNdXk0SGdEZndJa1VJMUNaeXBIcE1sTy1LR1lXMFhPZUNOQUpRdnFYZE1DYTF3QkxxcGRGTUlKQWFkYTYwaFhYaUZERU41SFIxblNWOUZFNm03NnJ2ajJOTWJuVVhQRmNtcjRwVDhtbGRzMFJOd0ltMmlLM1FxWEJfYWVzWTE2LXFpQm5pLUxZekE5NzFHdDYzTGxHcnM?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-01T07:00:00+00:00", "published_display": "01 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Pharmaceuticals (ASX:TLX) Stock Jumps 5.89%: FDA Resubmission Fuels Investor Optimism", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQVmdtLTN3bnBvNTRQQnpoX2dBU0dNS0FtV2ZpWHFrMV9ZVFByN0F1RGZPcU5zNWtJSTQ1cDNDalFQQm5SWlVMSWFfU2ZVUk5UR2RtQXVINzZHMklZa0FMVHQxNVkxdnlvU21xeDViZ0FYcU5naVNkUVNnSG9hUlB4WjJ6S2pJNGpQMDRaa2lDc01YVkRiVDRtbTlPM0p4NWgyT1FiRk55ODJ1ODNHQnYxNmxRYWM2d3VELUFoU0xJc1BPUnhz?oc=5", "source_name": "Kalkine", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara\u00ae) Brain Cancer Imaging Candidate", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNUEU4cmVQbnRQcWRWSHRKdWEwUFpYVkEtQkdlbm94Q19rSWQwcERUdThOZXBacXZ1TEJsc0hSQmFNUFRLTVRKaVlSTEw5Wm5KYk9XMVFZTk9SbnBxS3NjVGEyd0cyZm1oMkJ0VHFzbC1wRUZmM1FxWmxNMkFiaUozMXZoaFN4eGFRcW5OVms5TzV4eDJidE14STJyTU1XVUlLTGVKa2x0OGRQTS1URS1oTldjMFlNQTI2djdTNy0yMlo0VF9DMlptbFAyRWZPVm5rQm5EVWp1NVN2UUkw?oc=5", "source_name": "PR Newswire", "published_at": "2026-03-16T07:00:00+00:00", "published_display": "16 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock of the day: Telix Pharmaceuticals", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQOUUyMGZrcVF2YU9QVGhvMk1TaW0yTVhMODVEeG5CaU1IMUVTSXJvUEt0TnM2Y2hyYWhOeFdNckZpcWdRcWxyeVNxREVzbS1qc0R3aDhXcjgzVTY1cFlKcDVXNGoxSVFiMkRiVFU2ZkZxemdfNHhtWE54S2tVWHN5VVkzc1NNenFLNEp5R0oweUQtLUZQQkp3?oc=5", "source_name": "ig.com", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 105, "total_relevant": 66, "sentiment_summary": {"positive": 30, "negative": 4, "neutral": 32, "score": 58, "total": 66, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 85, "events": [{"event": "general", "label": "Market update", "weight": 25.1, "count": 45}, {"event": "earnings", "label": "Earnings", "weight": 4.95, "count": 11}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.75, "count": 5}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 30, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 11.14, "latest_week": "2026-07-10", "one_week_move": -6.1, "four_week_move": 16.5, "twelve_week_move": 3.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.395759, "market_dynamics_buy_signal": false, "relative_strength": -2.215255, "fair_value_gap": -11.3, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 47.0588, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.1% over one week, +16.5% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 69, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "Stock Titan", "count": 7}, {"label": "Simply Wall Street", "count": 5}, {"label": "Kalkine", "count": 4}, {"label": "PR Newswire", "count": 3}, {"label": "The National Law Review", "count": 3}, {"label": "Ad-hoc-news.de", "count": 2}, {"label": "TradingView", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 58}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 45}, {"label": "Earnings", "count": 11}, {"label": "Regulatory and legal", "count": 5}, {"label": "Guidance", "count": 2}, {"label": "Macro sensitivity", "count": 1}, {"label": "Analyst action", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "85/100 classification confidence."}, {"label": "Company focus", "value": "58", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-6.1% over one week, +16.5% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Telix opens radiopharmaceutical facility in Australia for cancer treatment"}], "updated_at": "2026-07-16T11:46:25.117939+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}